Kornimate/medical-research-clean huggingface dataset:
effect of scapular stabilization exercises versus virtual reality exercises in basketball players with scapular dyskinesia

Conditions: Scapular Dyskinesis

Summary: this study will be conducted to compare virtual reality and scapular stabilizing exercise among basketball player with scapular dyskinesia on scapular muscle performance, rounded shoulder, pain intensity , disability and hand grip strength

scapular dyskinesia (sd) is an alteration in the normal position or motion of the scapula during coupled scapulohumeral movements. it is lack of control of static or dynamic positioning of the scapula relative to the thorax. it affects from 64% to 100% of patients with shoulder lesions. scapular dyskinesia is a major etiological factor in overhead athletes' shoulder problems. virtual reality (vr) it allows individuals to interact and train with or within interesting and relatively realistic three-dimensional(3d) environments. vr and its simulated environments are well accepted in entertainment and computer game applications. however, what is not as well recognized is that vr offers the opportunity for intensive repetition of meaningful task-related activities necessary for effective rehabilitation. the scapular stabilization exercise in rehabilitation aims to restore shoulder function; these exercises are a combination of scapular stabilization exercises, rotator cuff strengthening exercises, range of motion (rom), proprioceptive neuromuscular facilitation (pnf), and stretching exercises. physiotherapy is the mainstay management for several musculoskeletal disorders. sixty basketball athletes with dyskinesea will be assigned randomly to three equal groups; the first will receive virtual reality exercise and routine exercise, and the second group will receive stabilization exercise and routine exercise. and finally, the third group will receive routine exercise only for eight weeks

Eligibility criteria:
inclusion criteria: * ninety basketball players of both genders. * subjects with age between 20 and 25 years old. * subjects with body mass index (bmi) ranging from 18 to 25 kg/m². exclusion criteria: * an injury within the four weeks before testing. * upper extremity fractures. * bilateral repetitive strain injuries * osteoarthritis on hand

Keywords: scapular stabilization virtual reality scapular dyskinesia
safety and efficacy of natalizumab in the treatment of crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active crohn's disease. it is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. these cells are thought to cause damage in the bowel leading to the symptoms of crohn's disease.


Eligibility criteria:
male and female patients at least 18 years of age who have at least a six-month history of crohn's disease and who are currently experiencing moderately to severely active crohn's disease. women must not be breastfeeding or pregnant, and must not become pregnant during the study.
initial hemato-immunological profile on the evolution of immunological thrombopenic purpura.

Conditions: Immune Thrombocytopenic Purpura; Autoimmune Thrombocytopenia; Thrombopenia

Summary: this study aims to determine the hemato-immunological parameters predictive of the evolution of a immune thrombocytopenic purpura (itp) towards chronicity, and to identify possible differences between the child and the adult.

immune thrombocytopenic purpura (itp) is a rare autoimmune thrombocytopenia whose incidence is 2 to 5 cases / 100,000 inhabitants / year. the potentially serious haemorrhagic risk is the major issue of management. a recent international consensus conference classifies pti according to the duration of thrombocytopenia: acute itp (\ 12 months) (rodeghiero 2009). in the acute or persistent phase, polyvalent immunoglobulins (ivig) and / or corticosteroids are proposed. in the chronic phase, splenectomy is a possible cure for 70% of patients. no predictor of treatment response is known. the pathophysiology of itp is multifactorial: platelet phagocytosis, mediated by autoantibody, macrophages of the reticuloendothelial system, and destruction in the spleen, genetic background and / or environmental factor favoring the role of certain lymphocyte subpopulations, cytotoxic or regulatory t, via their cytokine environment, abnormalities of thrombopoiesis. itp affects children as well as adults, but the evolutionary profile is very different. in children, itp, which is often post-infectious, is acute in 80% of cases, whereas itp in adults has a chronic evolution in 80% of cases. the primary diagnostic and therapeutic practices are similar. the reasons for these evolutionary differences are not known and little studied. is the orientation of the hemato-immunological response observed during the first episode of itp different in children and adults? do these differences explain the evolutionary specificities of the two age groups? are there hematologic parameters predictive of a response to initial treatments?

Eligibility criteria:
inclusion criteria: * minor patients aged 2 to 18 recruited at the children's hospital, in the service of prof. y. perel, dr. n. aladjidi, cerevance, * adult patients (\> 18 years old) recruited at the haut-lévêque hospital, pr jl pellegrin, pr jf viallard, gecai, * patient with acute immune thrombocytopenic purpura, seen at initial diagnosis or within 8 days (defined as thrombocytopenia \<100 g / l, after an infectious cause, drug or related to autoimmune disease, hematological malignancy or deficit immune have been eliminated, rodeghiero criteria, 2009). * patient who received immunoglobulins more than 4 weeks before inclusion * written consent given by the patient, if he is of age, or by the person (s) having parental authority * patient affiliated or beneficiary of a social security scheme exclusion criteria: * patient who has received specific treatment from an immune thrombocytopenic purpura * patient with secondary immune thrombocytopenic purpura (hematological malignancy, autoimmune disease, immunodeficiency, pregnancy) * patient placed under the protection of justice
immunity and nasal fungal colonization

Conditions: Colonization, Asymptomatic

Summary: fungal colonization causes opportunistic infection that may manifest when the host's immune status deteriorates. the purpose of this study was to determine the prevalence of fungal colonization in immunocompromised subjects compared to healthy controls.


Eligibility criteria:
inclusion criteria: * immunocompromised subjects included those who had known risk factors for fungal infection, including malignant diseases, diabetes, autoimmune disorders, renal or hepatic insufficiency, organ transplantation, or use of immunosuppressants * healthy volunteers had neither sinonasal symptoms nor nasal endoscopic inflammation. exclusion criteria: * patients were excluded if they were under 20 years old, were receiving antifungal medication, or were pregnant.

Keywords: colonization microbiota fungi immunocompromised
pharmacokinetic study of raltegravir in healthy premenopausal women.

Conditions: Pharmacokinetics

Summary: healthy subjects will take study drug by mouth twice a day for 7 consecutive days, blood and cervicovaginal samples will be taken most mornings around the am dose. two visits, \~14 hrs in length will be required on day 1 and 7. the purpose of this study is to measure how much raltegravir is found in the genital tract after taking it orally.

this study is looking at blood and cervicovaginal fluid (cvf) samples of healthy volunteers taking raltegravir. the purpose of this study is to measure the extent that raltegravir penetrates into other body compartments, such as the genital tract. subjects will take the study drug for 7 days, a total of 10 visits to the research center will be required. a screening visit will occur on no more than 28 days on days 1 and 7 the subject will stay in the research center for approximately 12 hours for scheduled blood and cvf sampling. days 3-6 and 8-9 will involve a short visit to the research center for one pre-dose blood and cvf sample before the morning dose. a follow up visit will occur about 7-10 days after last dose.

Eligibility criteria:
inclusion criteria: * healthy pre-menopausal female subjects * between the ages of 18 and 49 years * with an intact uterus and cervix (healthy is defined as no irregular menstrual cycles or clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests). exclusion criteria: * negative serum pregnancy test at screening and should be using at least one method of contraception * body mass index (bmi) of approximately 18 to 30 kg/m\^2 * and a total body weight \> 50 kg (110 lbs)
immunological and functional characterization of cellular population cd45+ infiltrating human glioblastoma

Conditions: Glioblastoma

Summary: despite advances in neurosurgery , radiotherapy and chemotherapy, the median survival in gbm patients is only 15 months from diagnosis. immunotherapy by checkpoint inhibitors (pd1 /pdl-1) appears as a promising treatment for many cancers. however, first clinical results are disappointing for gbm. an hypothesis is the immunosuppressive activity from infiltrating non-tumor cells. conversion of non-tumor cells from an immunosuppressive to an immuno-activating phenotype could be attempted in a therapeutic perspective.

an important and constant infiltration of cells marked with cd45 has been observed in 77 gbm studied for the prognostic value of pdl1 and il17 infiltration (in association with pr ghiringhelli ; inserm ; dijon) . however, cd45 is present at the surface of all leucocytes. the purpose of this project is to better characterize the nature and functionality of the cd45+ cells that infiltrate gbm (lymphocytes and their sub-types, macrophages, microglial cells). formalin-fixed paraffin-embedded gbm samples will be studied. a panel of immune cell antibody will be used for the immuno-histological (ih) study. furthermore, the investigator will compare these data with those obtained by the nanostring technology, a multiplexed measurement of gene expression.

Eligibility criteria:
inclusion criteria: * formalin-fixed paraffin-embedded gbm samples from tumor bank of the pathological laboratory of the university hospital of amiens-picardie. * histologic diagnosis of a glioblastoma according to the who classification of central nervous system * radical surgical removal in order to have enough histological material and to homogenize the main prognostic factor that is the surgical removal. * patients with more than 18 years old. * patients informed who have signed a consent form for using the tumor for research purposes without personal benefit. if patients were died, absence of objection known for the anonymous use of the tumor for scientific purpose. * be insured under one social security system. * committee for the protection of persons approval. exclusion criteria: * relapsed gbm * other brain tumors. * medical, psychological or social conditions not allowing the comprehension of the conduct of the study for patients able to give their opinion. * patient under curatorship.

Keywords: glioblastoma cd45 lymphocytes microglia macrophage
an integrated care platform based on the monitoring of older individual intrinsic capacity for inclusive health (careup)

Conditions: Old Age

Summary: the objective of this study is to assess the usability and acceptance of the careup solution in improving the quality of life at home of the older adults. the careup solution is a platform that collects data from different tools such as tablets, smartwatches, ambient sensors, ihealth weight scale, and digital hand dynamometer. .

the objective of this study is to assess the usability and acceptance of the careup solution at home in primary (older adults), secondary (informal caregivers) and tertiary (doctors and geriatrics) end users. the careup solution is a platform that collects data from different tools such as tablets, smartwatches, ambient sensors, ihealth weight scale, and digital hand dynamometer. the study will comprehends two phases: a pre-pilot and pilot phases.the pre-pilot phase will test new user interfaces and games with 5 older adult (primary users) and 5 informal caregiver (secondary) in each site (italy, romania, austria) for at least 1 week. this phase will only focus on primary endpoints (usability and acceptance). the pilot phase will investigate platform usability, acceptance and efficiency of developed intrinsic capacity (ic) evaluation algorithms, reliability and security. at least 30 primary and 15 secondary and some tertiary users (doctors and geriatrics) will be enrolled in each country (italy, romania, austria) for 12 months. this phase will focus on both primary and secondary endpoints.

Eligibility criteria:
inclusion criteria: * live independently in their home in rural or urban areas; * in good physical and cognitive status; * able to stand and walk unaided; * availability to sign the informed consent; * ability to use smartphones/tablets independently. exclusion criteria: * use of active implant or not-implant medical devices; * allergy to nickel components; * lack of written informed consent; * acute or untreated medical problems such as history of syncopal episodes, epilepsy and vertigo not controlled pharmacologically; serious dysfunction of the autonomic system; severe behavioural syndromes not compensated by drugs; concurrent neurological diseases; severe systemic diseases with life expectancy \< 1 year; * a myocardial infarction or stroke within 6 months; * painful arthritis, spinal stenosis, amputation, painful foot lesions or neuropathy limiting balance and mobility; * uncontrolled hypertension; * pacemaker or implantable cardioverter defibrillator; * diagnosis of mild and or/advanced parkinson's disease or other neuromuscular disorder; * diagnosis of mild and/or advance cognitive impairments * metastatic cancer or immunosuppressive therapy; * significant visual or hearing impairment

Keywords: ageing older adults artificial intelligence informal caregiver usability acceptance intrinsic capacity quality of life wellbeing loneliness ict-based solution
experimental study of detection an intentional performance degradation in grip strength

Conditions: Pain

Summary: in this study, the detection of the feigning weakness in grip strength is measured using different grip strength testing instruments. patients with injury of the upper limb are compared to patients with injury of the lower limb as well as healthy controls.


Eligibility criteria:
inclusion criteria: - \>18 years, signed consent form, stable pain mediaction for 48 hours exclusion criteria: - \<18, unsigned consent form, dose change of the pain medication during the last 48 hours...
investigation of surgical sectioning of the filum terminale in treating occult tethered cord syndrome patients

Conditions: Tethered Cord; Tethered Cord Syndrome; Occult Spina Bifida; Spina Bifida Occulta

Summary: the investigators hypothesize that surgical release of the filum terminale (strand of fibrous tissue at the end of the spinal cord) is a more efficacious treatment option for symptomatic relief than medical management in subjects with occult tethered cord syndrome (otcs) and that the risks do not outweigh the benefit profile.

this is a phase ii pilot randomized-controlled, single-site trial to determine if surgical untethering of the filum terminale is more effective, preliminarily, than medical management as a treatment option for otcs. subjects will be randomized to one of two arms: surgical untethering or medical management only. symptom improvement and adverse events will be assessed and recorded for 1 year from initiation of treatment. after a minimum of 1 year, subjects who were randomized to the medical management arm may cross over to the surgical arm if the pi deems it is in the subject's best interest to do so. the exploratory hypothesis is that surgery for otcs is both safe and more effective than medical management at relieving the symptoms of otcs.

Eligibility criteria:
inclusion criteria: * male or female ≥ 2 and \< 80 years of age. * refractory to medical management of symptoms for at least 1 year. * documentation of otcs, as defined by a total score of at least 30 on the following scale: occult grading scale (score 0-100) orthopedic abnormality: 0-15; central nervous system dysfunction: 0-25; cutaneous stigmata: 0-10; urological or bowel dysfunction: 0-25; lumbosacral anatomy: 0-15; tissue integrity disorder: 0-10. exclusion criteria: * subjects \ 80 years of age. * radiographically identified tethered cord, as defined by any of the following: * a low-lying conus (at or below the l2-3 disc space) * a thickened filum (\>2 mm) * fat in the filum or lipoma * distinct adhesion or tethering. * a history of meningocele manqué or myelomeningocele. * cutaneous markings of dermal sinus tract. * history of prior surgery on the lumbar spine. * history of prior surgery for spinal dysraphism. * history of prior infection or autoimmune condition of the central nervous system.

Keywords: tethered cord occult filum terminale tight filum
danish randomized trial on leadless vs transvenous pacing

Conditions: AV Block

Summary: the purpose of this study is to evaluate the quality of life, patient acceptance and exercise capacity with leadless compared to transvenous pacing in elderly patients with new-onset high-grade atrioventricular block. consecutive patients with high-grade atrioventricular black and preserved sinus node function with indication for permanent pacemaker implantation according to the latest european guidelines, are included in a prospective, partly patient and accessor blinded and partly open label, 1:1 randomized combined parallel and cross-over trial to implantation with 1) a micra av transcathter pacing system or 2) an azure xt dr dual chamber pacemaker.


Eligibility criteria:
inclusion criteria: * first time pacemaker implantation on class i or ii esc recommendations for avb with an expected amount of right ventricular pacing \>80% of the time, * age 75 years or older * intact sinus node function * expected survival more than 12 months based on clinical evaluation * able to provide informed consent exclusion criteria: * persistent or previous cardiac implantable electronic device i.e., pacemaker, icd, or crt. * persistent, or chronic atrial fibrillation * reversible avb * transient avb due to ongoing ischemia * heart failure nyha class iii-iv * heart failure with branch block and indication for crt implantation, irrespective of nyha class * indication for primary or secondary prophylactic icd implantation * acute myocardial infarction (ami) within 3 months * severe chronic pulmonary disease with pulmonal hypertension limiting exercise capacity * expected survival \< 12 months based on clinical evaluation * performing high intensity sport * participation in another trial with experimental treatment * contraindication against device implantation (e.g., concurrent infection) * failure to provide informed consent

Keywords: leadless pacing cardiac pacemaker cardiac arrythmia heart disease
comparison of prp & dfdba vs. dfdba in intrabony periodontal defects

Conditions: Chronic Periodontitis

Summary: the purpose of this clinical trial is to compare the results in subjects with periodontitis using subjects own blood - platelet-rich plasma (prp) combined with bone graft material, namely, demineralized freeze - dried bone allograft (dfdba) or dfdba alone in the treatment of bone defects around the teeth.

after being informed about the study and potential risks, 13 patients giving written informed consent and who meet the eligibility requirements were randomly allocated in a single blind manner (participants) to test group (prp combined with dfdba) or control group (dfdba). 33 sites (18 test, 15 control unpaired defects) were treated - 1) to investigate the possible additional effects of prp when combined with dfdba, and 2) to compare the clinical and radiographic outcomes obtained in test and control groups,12 months post - operatively.

Eligibility criteria:
inclusion criteria: * outpatients * with chronic periodontitis * who were free of local or systemic disease * who had not received any type of periodontal therapy in the last six months * radiograph showing at least one angular defect in any quadrant * the involved teeth were vital and asymptomatic * the site of interest had at least 2 mm of keratinized gingiva on the facial aspect of the selected teeth exclusion criteria: * patients with abnormal platelet count * allergic to chlorhexidine or any other medicine used in the study * showing unacceptable oral hygiene compliance during / after the phase i therapy; * pregnant or lactating mothers; * smokers * endodontically involved teeth * patients under any medication known to interfere with periodontal healing. e.g., corticosteroids * on anticoagulant therapy * patients with transferable jobs or who were uncooperative * patients participating in other dental clinical trials.

Keywords: platelet - rich plasma demineralized freeze - dried bone allograft intrabony defect periodontitis.
safety and efficacy of vilazodone in pediatric patients with major depressive disorder (vlz-md-22)

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.


Eligibility criteria:
inclusion criteria: * male or female outpatients between 7-17 years of age * primary diagnosis of major depressive disorder (mdd) * children's depression rating scale-revised (cdrs-r) score of 40 or greater * clinical global impressions-severity (cgi-s) score of 4 or greater exclusion criteria: * current (past 3 months) principal diagnostic and statistical manual of mental disorders, 4th edition, text revision (dsm-iv-tr) based diagnosis of an axis disorder other than major depressive disorder (mdd) that is the primary focus of treatment. * history of suicidal behavior, or requires precaution against suicide * not generally healthy medical condition * seizure disorder